Method and compositions for identifying anti-HIV therapeutic compounds
Granted: June 24, 2004
Application Number:
20040121316
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
Granted: May 13, 2004
Application Number:
20040091931
Described herein are methods for identifying and preparing bivalent binding molecules to 7 transmembrane G protein-coupled receptors. The methods disclosed herein are based on the SELEX method for generating high affinity nucleic acid ligands. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The methods of this invention combine two or more binding domains to two or more different epitopes of the same 7 transmembrane G protein-coupled receptor. These…
2'-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
Granted: March 18, 2004
Application Number:
20040053271
Methods are described for the identification and preparation of nucleic acid ligands to calf intestinal phosphatase. Included in the invention are specific RNA ligands to calf intestinal phosphatase identified by the SELEX method.
High affinity nucleic acid ligands to lectins
Granted: March 4, 2004
Application Number:
20040043923
This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin, E-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands.
Nucleoside modifications by palladium catalyzed methods
Granted: February 19, 2004
Application Number:
20040034212
This invention discloses a method for the preparation of 2′-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.
Nucleic acid ligands
Granted: October 23, 2003
Application Number:
20030198989
This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high…
High affinity nucleic acid ligands of complement system proteins
Granted: October 9, 2003
Application Number:
20030191084
Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
High affinity oligonucleotide ligands to growth factors
Granted: September 25, 2003
Application Number:
20030180744
Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;, PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGF&bgr;1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by the SELEX method. Further included are RNA ligands that inhibit the interaction of TGF&bgr;1 and hKGF with their receptors and DNA ligands that inhibit the interaction of…
High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
Granted: September 18, 2003
Application Number:
20030176680
Methods are described for the identification and preparation of nucleic acid ligand ligands to vascular endothelial growth factor (VEGF). Included in the invention are specific RNA ligands to VEGF identified by the SELEX method.
Nucleic acid ligand complexes
Granted: July 3, 2003
Application Number:
20030125263
This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a…
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
Granted: June 19, 2003
Application Number:
20030114404
This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic,…
Tenascin-C nucleic acid ligands
Granted: June 5, 2003
Application Number:
20030104377
Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.
Systematic evolution of ligands by exponential enrichment: blended SELEX
Granted: April 24, 2003
Application Number:
20030077646
A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO: 1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (SEQ ID NO: 2). This…
High affinity nucleic acid ligands of complement system proteins
Granted: April 24, 2003
Application Number:
20030078221
Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
Urea nucleosides as therapeutic and diagnostic agents
Granted: April 10, 2003
Application Number:
20030069414
Modified nucleosides and methods of making and using the nucleosides are disclosed. The compounds can be prepared by reacting nucleoside starting materials that contain a suitable leaving group at one or more of the carbon atoms in the purine or pyrimidine ring, with a vinylstannane, carbon monoxide, and a palladium catalyst to provide 1-ene-3-one intermediates. These intermediates are then reacted with suitably functionalized primary or secondary amines via a Michael reaction. When the…
Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
Granted: March 13, 2003
Application Number:
20030049644
The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
Truncation selex method
Granted: January 2, 2003
Application Number:
20030003461
This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
Aptamers as reagents for high throughput screening
Granted: December 26, 2002
Application Number:
20020197617
The invention relates to the use of aptamers in high throughput screening methods to determine whether a non-nucleic acid molecule, i.e. small molecule, binds to a target.
Methods of producing nucleic acid ligands
Granted: November 21, 2002
Application Number:
20020172962
The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.
Preparation of cyclohexene carboxylate derivatives
Granted: October 24, 2002
Application Number:
20020156300
The present invention provides new synthetic methods and compositions. In particular, new methods of preparing intermediates useful in the synthesis of neuraminidase inhibitors and compositions useful as intermediates that are themselves useful in the synthesis of neuraminidase inhibitors are provided.
